- Home
- NUVL
NUVL
Nuvalent Inc.
as 05-20-2024 10:34am EST
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 4.4B | IPO Year: | 2021 |
| Target Price: | $89.78 | AVG Volume (30 days): | 482.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $38.14 - $89.39 | Next Earning Date: | 05-09-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of Nuvalent Inc. (NUVL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Shair Matthew | NUVL | Director | May 6 '24 | Sell | $70.27 | 7,900 | $555,133.00 | 1,462,198 | SEC Form 4 |
| Shair Matthew | NUVL | Director | May 6 '24 | Sell | $69.27 | 29,600 | $2,050,392.00 | 1,470,098 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | May 2 '24 | Sell | $73.13 | 138 | $10,091.94 | 33,300 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | May 2 '24 | Sell | $72.58 | 1,296 | $94,063.68 | 33,438 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | May 2 '24 | Sell | $71.55 | 1,566 | $112,047.30 | 34,734 | SEC Form 4 |
| Shair Matthew | NUVL | Director | Apr 22 '24 | Sell | $64.52 | 14,650 | $945,218.00 | 1,537,198 | SEC Form 4 |
| Shair Matthew | NUVL | Director | Apr 22 '24 | Sell | $63.80 | 8,694 | $554,677.20 | 1,551,848 | SEC Form 4 |
| Shair Matthew | NUVL | Director | Apr 22 '24 | Sell | $62.66 | 14,156 | $887,014.96 | 1,560,542 | SEC Form 4 |
| Shair Matthew | NUVL | Director | Apr 15 '24 | Sell | $65.27 | 25,600 | $1,670,912.00 | 1,586,598 | SEC Form 4 |
| Shair Matthew | NUVL | Director | Apr 15 '24 | Sell | $66.17 | 11,900 | $787,423.00 | 1,574,698 | SEC Form 4 |
| Shair Matthew | NUVL | Director | Apr 8 '24 | Sell | $67.89 | 11,022 | $748,283.58 | 1,638,676 | SEC Form 4 |
| Shair Matthew | NUVL | Director | Apr 8 '24 | Sell | $68.63 | 25,478 | $1,748,555.14 | 1,613,198 | SEC Form 4 |
| Shair Matthew | NUVL | Director | Apr 8 '24 | Sell | $69.64 | 1,000 | $69,640.00 | 1,612,198 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Apr 4 '24 | Sell | $71.54 | 731 | $52,295.74 | 35,569 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Apr 4 '24 | Sell | $72.69 | 400 | $29,076.00 | 35,169 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Apr 4 '24 | Sell | $73.74 | 378 | $27,873.72 | 34,791 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Apr 4 '24 | Sell | $74.81 | 1,491 | $111,541.71 | 33,300 | SEC Form 4 |
| Shair Matthew | NUVL | Director | Apr 1 '24 | Sell | $77.19 | 9,694 | $748,279.86 | 1,649,698 | SEC Form 4 |
| Shair Matthew | NUVL | Director | Apr 1 '24 | Sell | $76.82 | 27,806 | $2,136,056.92 | 1,659,392 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Mar 28 '24 | Sell | $74.23 | 2,748 | $203,984.04 | 52,552 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Mar 28 '24 | Sell | $75.22 | 16,208 | $1,219,165.76 | 36,344 | SEC Form 4 |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Mar 28 '24 | Sell | $75.94 | 3,044 | $231,161.36 | 33,300 | SEC Form 4 |
| Shair Matthew | NUVL | Director | Mar 25 '24 | Sell | $76.74 | 35,545 | $2,727,723.30 | 1,689,153 | SEC Form 4 |
| Shair Matthew | NUVL | Director | Mar 25 '24 | Sell | $77.37 | 1,955 | $151,258.35 | 1,687,198 | SEC Form 4 |
| Shair Matthew | NUVL | Director | Mar 25 '24 | Sell | $76.74 | 1,895 | $145,422.30 | 238,627 | SEC Form 4 |
Latest Nuvalent Inc. News
NUVL Breaking Stock News: Dive into NUVL Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing
Pharmaceutical Technology
3 days ago
FDA grants breakthrough therapy status for Nuvalent’s NVL-655
MT Newswires
4 days ago
Nuvalent Gets Breakthrough Therapy Designation for Lung Cancer Treatment Candidate
PR Newswire
4 days ago
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
MT Newswires
11 days ago
Nuvalent Q1 Net Loss Widens
PR Newswire
11 days ago
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
MT Newswires
12 days ago
Nuvalent Insider Sold Shares Worth $2,605,525, According to a Recent SEC Filing
Zacks
12 days ago